$HSTO News
Last published 3y ago
- 3y agoHSTOHistogen Announces Board Approval of Complete Liquidation and DissolutionGlobeNewswireSAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan
- 3y agoHSTOHistogen to Explore Strategic AlternativesGlobeNewswireSAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and
- 3y agoHSTOHistogen Reports First Quarter 2023 Results and Provides Business UpdateGlobeNewswireReceived FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in
- 3y agoHSTOHistogen Announces Online Publication in the Journal of Investigative DermatologyGlobeNewswireEmricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 20,
- 3y agoHSTOHistogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins UniversityGlobeNewswireLicensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April
- 3y agoHSTOHistogen Announces Issuance of US Patent Covering CTS-2090 Methods of UseGlobeNewswireThe Newly Issued Patent is Expected to Provide Protection into 2040 Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE)
- 3y agoHSTOHistogen Reports Year-End 2022 Results and Provides Business UpdateGlobeNewswireSAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase
- 3y agoHSTOHistogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and
- 3y agoHSTOAmerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led ArbitrationBusiness WireAmerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19. Amerimmune LLC had a discovery early in 2020, showing
- 3y agoHSTOHistogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific OfficerGlobeNewswireSAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and
- 4y agoHSTOHistogen Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireSAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase
- 4y agoHSTOHistogen Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireClosed $5M Financing in July Regained Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative ther
- 4y agoCVMHSTOTXMDATISCEL-SCI Appoints Dr. Gail Naughton to Its Board of DirectorsBusiness WirePioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naugh
- 4y agoHSTOHistogen to Report Second Quarter 2022 Financial Results and Provide Business UpdateGlobeNewswireSAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious an
- 4y agoHSTOHistogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireSAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious an
- 4y agoHSTOHistogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireSAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious an
- 4y agoHSTOHistogen Announces 1-for-20 Reverse Stock SplitGlobeNewswireSAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious an
- 4y agoHSTOHistogen to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireSAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and
- 4y agoHSTOHistogen Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireReceived $3.75 Million Payment from Allergan Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:
- 4y agoHSTOParacrine Announces Appointment of Biotech Veteran David Crean, Ph.D. to the Board of DirectorsBusiness WireParacrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, announced today the appointment of David Crean, Ph.D. as an independent Director of the company. "We are delighted to welcome
- 4y agoHSTOHistogen to Report First Quarter 2022 Financial Results and Provide Business UpdateGlobeNewswireSAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious a
- 4y agoHSTOHistogen Announces Closing of $4.75 Million Private PlacementGlobeNewswireSAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological
- 4y agoAMCDIDIHSTOMULN+1Thinking about buying stock in AMC Entertainment, Mullen Automotive, DiDi Global, Exela Technologies, or Histogen?PR NewswireNEW YORK, March 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, MULN, DIDI, XELA, and HSTO.
- 4y agoHSTOHistogen Announces $4.75 Million Private PlacementGlobeNewswireSAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological
- 4y agoHSTOHistogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business UpdateGlobeNewswireSAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious a
- 4y agoHSTOHistogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business UpdateGlobeNewswireSAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healt
- 4y agoHSTOHistogen Announces Closing of $3.5 Million Private PlacementGlobeNewswireSAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological
- 4y agoHSTOHistogen Announces $3.5 Million Private PlacementGlobeNewswireSAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological
- 5y agoHSTOHistogen Reports Third Quarter 2021 Earnings and Provides Business UpdateGlobeNewswirePhase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee On-Going with Top-Line Data Expected in the Second Half of 2022 IND Filing for HST 004 for Spinal Disc Repair Anticipated in the Third Quarter of 2022 Pre-Clinical Proof-of-C
- 5y agoHSTOHistogen Announces CEO TransitionGlobeNewswireSAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain health
- 5y agoHSTOHistogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, Asthma, and Immunology ConferenceGlobeNewswirePhase 1 Study in Mild COVID-19 Patients Demonstrated a Favorable Safety and Tolerability Profile and Statistically Significant Clinical Symptom and Biomarker Improvements Additional Analysis Demonstrates Caspase Inhibition Proactively Modulates the Im
- 5y agoHSTOHistogen to Report Third Quarter 2021 Financial Results on November 10, 2021GlobeNewswireSAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain health
- 5y agoHSTOHistogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 PatientsGlobeNewswireImmunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression Emricasan Found to Have Statistically Significant Improvements in Clinically Relevant Hematological and Immune Markers Which May Lead to Potential Clinical B
- 5y agoHSTOHistogen Reports Second Quarter 2021 Earnings and Provides Business UpdateGlobeNewswireCompany to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates Initiated Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee HST 004 Selected as Product Candidate for Spinal Disc Repair with
- 5y agoHSTOHistogen to Present at the Canaccord Genuity 41st Annual Growth ConferenceGlobeNewswireSAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain health
- 5y agoHSTOHistogen to Report Second Quarter 2021 Financial Results on August 11, 2021GlobeNewswireSAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain health
- 5y agoHSTOHistogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage RegenerationGlobeNewswireSAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced the initiation of its Phase 1/2 clinical trial of HST 003 to evaluate the safety and efficacy of human extracellular matrix (hECM:HST 003) implanted within microf
- 5y agoBIOCCLOVHSTOIDRA+1Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?PR NewswireNEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, HSTO, IDRA, STSA, and CLOV. T
- 5y agoHSTOHistogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 PatientsGlobeNewswireEmricasan Found to be Safe and Well Tolerated with No Serious Adverse Events Patients Completing Treatment with Emricasan had a Complete Resolution of the Symptoms Most Commonly Associated in Mild COVID-19 At Day 7 Continuing to Day 45 SAN DIEGO, J
- 5y agoHSTOHistogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireSAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain health
- 5y agoHSTOHistogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireSAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain health
- 5y agoHSTOHistogen Provides Update on its Development Programs and Pipeline FocusGlobeNewswireCompany to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates HST 003 Trial for Cartilage Regeneration in the Knee Remains On-Track with an Anticipated Phase 1/2 Study Initiation in June 2021 HST 004
- 5y agoHSTOHistogen and Amerimmune Report Publication on Emricasan in COVID-19GlobeNewswireSAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy
- 5y agoHSTOHistogen Reports First Quarter 2021 Earnings and Provides Business UpdateGlobeNewswireStrengthened Balance Sheet with $20.8 Million of Gross Proceeds from Financing and Warrant Exercises Initiated Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients with Top-Line Data Anticipated in the Second Quarter of 2021 Initiation of Ph
- 5y agoHSTOHistogen to Report Second Quarter 2021 Financial Results and Provide Business UpdateGlobeNewswireSAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healt
- 5y agoHSTOHistogen to Present at the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSAN DIEGO, March 30, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
- 5y agoHSTOHistogen Appoints Rochelle Fuhrmann to Board of DirectorsGlobeNewswireSAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
- 5y agoHSTOSafety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19 - NCT04803227ClinicalTrials.govNumber of participants with treatment-related adverse events as assessed by CTCAE v4.0, Patient reported outcomes as assessed by COVID-19 assessment tool, Number of participants that experience death during the study., (and 9 more...)
- 5y agoHSTOHistogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 PatientsGlobeNewswireSAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) and Amerimmune LLC today announced dosing the first patient in a Phase 1 study of emricasan in mild symptomatic -COVID-19...
- 5y agoHSTOHistogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage RegenerationGlobeNewswireTrial Initiation Anticipated in Second Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) --...